

## RESEARCH ARTICLE

# Human BDCA2<sup>+</sup>CD123<sup>+</sup>CD56<sup>+</sup> dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset

Haisheng Yu<sup>1,3</sup>, Peng Zhang<sup>2,3</sup>, Xiangyun Yin<sup>1,3</sup>, Zhao Yin<sup>4</sup>, Quanxing Shi<sup>4</sup>, Ya Cui<sup>2</sup>, Guanyuan Liu<sup>5</sup>,  
Shouli Wang<sup>4</sup>, Pier Paolo Piccaluga<sup>6</sup>, Taijiao Jiang<sup>2</sup>✉, Ligu Zhang<sup>1</sup>✉

<sup>1</sup> Key Laboratory of Immunity and Infection, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

<sup>2</sup> Key Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

<sup>3</sup> Graduate School of the Chinese Academy of Sciences, Beijing 100080, China

<sup>4</sup> Department of Cardiology, 306th Hospital of PLA, Beijing 100101, China

<sup>5</sup> Department of Gynecology and Obstetrics, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

<sup>6</sup> Department of Experimental, Diagnostic, and Specialty Medicine, Hematopathology & Hematology Sections, Molecular Pathology Laboratory, S. Orsola-Malpighi Hospital, Bologna University, Bologna 40126, Italy

✉ Correspondence: taijiao@moon.ibp.ac.cn (T. Jiang), liguozhang@ibp.ac.cn (L. Zhang)

Received December 10, 2014 Accepted December 25, 2014

## ABSTRACT

Dendritic cells (DCs) comprise two functionally distinct subsets: plasmacytoid DCs (pDCs) and myeloid DCs (mDCs). pDCs are specialized in rapid and massive secretion of type I interferon (IFN-I) in response to nucleic acids through Toll like receptor (TLR)-7 or TLR-9. In this report, we characterized a CD56<sup>+</sup> DC population that express typical pDC markers including CD123 and BDCA2 but produce much less IFN-I comparing with pDCs. In addition, CD56<sup>+</sup> DCs cluster together with mDCs but not pDCs by genome-wide transcriptional profiling. Accordingly, CD56<sup>+</sup> DCs functionally resemble mDCs by producing IL-12 upon TLR4 stimulation and priming naïve T cells without prior activation. These data suggest that the CD56<sup>+</sup> DCs represent a novel mDC subset mixed with some pDC features. A CD4<sup>+</sup>CD56<sup>+</sup> hematological malignancy was classified as blastic plasmacytoid dendritic cell neoplasm (BPDCN) due to its expression of characteristic molecules of pDCs.

Haisheng Yu and Peng Zhang have contributed equally to this work

**Electronic supplementary material** The online version of this article (doi:10.1007/s13238-015-0140-x) contains supplementary material, which is available to authorized users.

However, we demonstrated that BPDCN is closer to CD56<sup>+</sup> DCs than pDCs by global gene-expression profiling. Thus, we propose that the CD4<sup>+</sup>CD56<sup>+</sup> neoplasm may be a tumor counterpart of CD56<sup>+</sup> mDCs but not pDCs.

**KEYWORDS** dendritic cells, CD56<sup>+</sup> DC, pDC, mDC, BPDCN

## INTRODUCTION

Dendritic cells (DCs) are professional antigen-presenting cells found in virtually all tissues. The main function of DCs is to induce T-cell activation, polarization and expansion against invading pathogens while maintaining tolerance to self antigens (Steinman, 2007). Three DC subsets have been identified in the human blood: plasmacytoid dendritic cell (pDC) and two subsets of myeloid DC (mDC) expressing CD1c (BDCA1) and CD141 (BDCA3) respectively (Dziona et al., 2000; Ziegler-Heitbrock et al., 2010). pDCs are characterized by their specific expression of CD123, BDCA2, BDCA4 and ILT7 (Dziona et al., 2000; Cao et al., 2006; Rissoan et al., 2002). In addition, pDCs express high levels of interferon regulatory factor 7 (IRF7), Toll like receptor

(TLR)-7 and TLR-9. Accordingly, they produce large amounts of type I interferon (IFN-I) upon stimulation with nucleic-acid ligands of TLR7/TRL9 (Siegal et al., 1999; Celli et al., 1999). Transcription factors E2-2 and Spi B are specifically expressed in pDCs and play important roles in their development and maintenance (Cisse et al., 2008; Schotte et al., 2004).

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy characterized by the clonal proliferation of pDC-like cells (Facchetti et al., 2008). Neoplastic cells from BPDCN patients express pDC specific molecules, such as BDCA2, CD123, CD4, TCL1, Bcl11A, CD2AP and Spi B (Petrella and Facchetti, 2010). Additionally, BPDCN cells can produce IFN-I upon TLR7 and TLR9 ligands stimulation although at much lower level comparing with pDCs (Chaperot et al., 2001). Interestingly, BPDCN cells also express CD56, which is not present on the majority of pDCs (Grouard et al., 1997). A small population of DCs in normal or FLT3 mobilized human blood do express CD56, which have been proposed as a pDC subpopulation that gives rise to BPDCN (Petrella et al., 2002; Comeau, 2002).

In this report, we characterized these BDCA2<sup>+</sup> CD123<sup>+</sup>CD56<sup>+</sup> DCs from human peripheral blood. Although they express some pDC featured molecules, the transcriptomic and functional characterizations indicate that they belong to mDCs rather than pDCs.

## RESULTS

### CD56<sup>+</sup> DCs are functionally distinct from pDCs

BDCA2 and CD123 are commonly used for the identification of human pDCs in the blood and lymphoid tissues. A subpopulation of BDCA2<sup>+</sup>CD123<sup>+</sup>CD56<sup>+</sup> (CD56<sup>+</sup>) DCs have been reported in human blood and proposed as a pDC subpopulation related to BPDCN (Petrella et al., 2002; Comeau, 2002). We first confirmed the presence of CD56<sup>+</sup> subset in the HLA-DR<sup>+</sup>, CD11c<sup>-</sup>, BDCA2<sup>+</sup> and CD123<sup>+</sup> DCs in human blood (Fig. 1A and 1B). The CD56<sup>+</sup> subset represents about 5% of the BDCA2 and CD123 double positive cells (Fig. 1B,  $n = 15$ ). It was reported that pDCs can be divided into two populations by their CD2 expression (Matsui et al., 2009). We found that the CD56<sup>+</sup> DCs universally express CD2 (Fig. 2A).

Next, we purified the CD56<sup>+</sup> and CD56<sup>-</sup> cells to compare their IFN-I production by TLR7 or TLR9 stimulation. In order to get higher purity, we added CD2 in our purification protocol, thus CD123<sup>+</sup>CD2<sup>+</sup>CD56<sup>+</sup> and CD123<sup>+</sup>CD2<sup>-</sup>CD56<sup>-</sup> DCs were sorted by FACS for further analysis. Usually the purity of CD2<sup>-</sup>CD56<sup>-</sup> cells was over 95% and the purity of CD2<sup>+</sup>CD56<sup>+</sup> cells was over 80% with contamination of some CD2<sup>+</sup>CD56<sup>-</sup> cells (Fig. 2B). High level IFN $\alpha$  production upon TLR7 or TLR9 stimulation is the key characteristic of pDCs. However, purified CD56<sup>+</sup> DCs produced much less IFN $\alpha$  upon CpG A stimulation comparing to CD56<sup>-</sup> cells from same donors (around 10%) (Fig. 2C, left panel). Similar

results were also observed when the purified DCs were stimulated with influenza virus (Fig. 2C, right panel). In order to exclude the effect of CD56 antibody binding during purification, we also compared the IFN $\alpha$  production capacity of CD56<sup>+</sup> and CD56<sup>-</sup> DCs by intracellular staining without prior purification. When enriched DCs were stimulated with CpG A and stained IFN $\alpha$  intracellularly, above 70% of CD56<sup>-</sup> cells but only 10% CD56<sup>+</sup> cells expressed IFN $\alpha$  (Fig. 2D, left panel). Similar results were observed by R848, a TLR7 ligand stimulation (Fig. 2D, right panel).

### CD56<sup>+</sup> DCs clustered together with mDCs but not pDCs by transcriptomic analysis


In order to compare the gene expression of CD56<sup>+</sup> DCs and other DC subsets at whole genome level, we analyzed the transcriptome of both CD56<sup>+</sup> pDCs and CD56<sup>+</sup> DCs by RNA sequencing (RNA-seq). Next, we compared the transcriptional profile of CD56<sup>+</sup> DCs with cDNA array data of human DC subsets retrieved from public databases (Robbins et al., 2008). There were 772 genes expressed in CD56<sup>+</sup> DCs at higher level (over 2 times) than those of CD56<sup>-</sup> DCs and 2398 genes vice versa. Among those, 648 genes highly expressed in CD56<sup>+</sup> cells (Fig. 3A, left panel) and 1557 lowly expressed ones (Fig. 3B, left panel) were present in the cDNA array data of human blood DC subsets (Robbins et al., 2008). And the names of those differentially expressed genes are provided in Table S1 and S2. Intriguingly, 547 (91%) CD56<sup>+</sup> DC highly expressed genes present at higher level in mDCs than pDCs based on cDNA array data (Fig. 3A, right panel; Table S1). Similarly, 1292 (83%) CD56<sup>+</sup> DCs lowly expressed genes presented at lower level in mDCs than pDCs (Fig. 3B, right panel; Table S2).

To clarify the relationship of CD56<sup>+</sup> DCs and other DC subsets, we normalized our RNA-Seq data with cDNA data, then did hierarchical clustering with complete linkage and principal component analysis (PCA) (11,372 genes). Both analyses showed that CD56<sup>-</sup> DCs clustered together with pDCs as expected, while the CD56<sup>+</sup> DCs clustered together with BDCA3 and BDCA1 mDCs (Fig. 3C and 3D).


### CD56<sup>+</sup> DCs are functionally analogous to mDCs

TLR expression patterns of pDCs and mDCs are drastically different. pDCs preferentially express TLR7 and TLR9 while mDCs express higher levels of TLR2 and TLR4 (Liu 2005; Cerboni et al., 2013). We found that the expression level of TLR4 (Fig. 4A) and the amount of TNF $\alpha$  produced upon LPS stimulation (Fig. 4B and 4C) were similar between CD56<sup>+</sup> DCs and mDCs. Moreover, CD56<sup>+</sup> DCs could produce IL-12 at a comparable level to mDCs at both RNA (Fig. 4D) and protein level (Fig. 4E). While pDCs did not produce IL-12 (Fig. 4D and 4E) as previously reported (Kadowaki et al., 2001).

Different from pDCs, mDCs could prompt T-cell proliferation without prior stimulation or activation. In order to




**Figure 1. CD56<sup>+</sup> DCs in human blood.** (A) Human PBMC were first gated based on light scatters, and dead cells were excluded by yellow fluorescent reactive dye (L/D dye), then Lin<sup>-</sup>HLA-DR<sup>+</sup>BDCA2<sup>+</sup>CD123<sup>+</sup> dendritic cells (DCs) were gated for further analysis. (B) Gated Lin<sup>-</sup>HLA-DR<sup>+</sup>BDCA2<sup>+</sup>CD123<sup>+</sup> blood DCs were divided into two subsets by their CD56 expression. (C) Summarized data show relative abundance of CD56<sup>-</sup> and CD56<sup>+</sup> populations in BDCA2<sup>+</sup>CD123<sup>+</sup> DCs (Mean  $\pm$  SD,  $n = 15$ ).



**Figure 2. CD56<sup>+</sup> DCs are functionally distinct from pDCs.** (A) Human PBMC were gated on Lin<sup>-</sup>HLA-DR<sup>+</sup>CD11c<sup>-</sup>CD123<sup>+</sup> DCs, and the gated DCs were analyzed by their CD2 and CD56 expression. (B) Lineage depleted PBMC were gated on Lin<sup>-</sup>HLA-DR<sup>+</sup>CD11c<sup>-</sup>CD123<sup>+</sup> DCs, then CD2<sup>+</sup>CD56<sup>+</sup> and CD2<sup>-</sup>CD56<sup>-</sup> DCs were sorted by FACS. The purities of sorted cells are shown in each plot. (C) 10,000 purified CD123<sup>+</sup>CD56<sup>-</sup> and CD123<sup>+</sup>CD56<sup>+</sup> DCs were stimulated with CpG A or influenza virus (Flu) for 24 h, then interferon  $\alpha$  (IFN $\alpha$ ) in the supernatants were analyzed by ELISA. Data summarized from 3 independent donors. (D) Lineage depleted PBMCs were stimulated with CpG A or R848 then analyzed by FACS for surface markers and IFN $\alpha$  intracellularly. Lin<sup>-</sup>HLA-DR<sup>+</sup>CD11c<sup>-</sup>CD123<sup>+</sup> cells were gated and plotted for CD56 and IFN $\alpha$ . The numbers in each quadrant represent percentage of total gated cells. One out of four independent experiments is shown.

further characterize the relationship between CD56<sup>+</sup> DCs, pDCs and mDCs, we examined more gene expression that related to antigen presentation. MHC II molecules and CD86


were highly expressed on CD56<sup>+</sup> DCs compared to pDCs at RNA level (Table S3). These were confirmed at protein level by FACS analysis (Fig. 4F). Gamma-interferon-inducible



**Figure 3. Comparing gene expression of CD56<sup>+</sup> DCs and other DC subsets.** (A) 648 genes expressed in CD123<sup>+</sup>CD56<sup>+</sup> DCs at least two fold higher than in CD123<sup>-</sup>CD56<sup>-</sup> DCs obtained by RNA-Seq (left panel) and their expressions in pDCs, BDCA3 mDCs and BDCA1 mDCs extracted from cDNA array data (right panel). (B) 1557 lowly expressed genes in CD123<sup>+</sup>CD56<sup>+</sup> relative to CD123<sup>-</sup>CD56<sup>-</sup> DCs (left panel) and their expressions in pDCs, BDCA3 mDCs and BDCA1 mDCs extracted from cDNA array data (right panel). (C) Clustering of CD123<sup>+</sup>CD56<sup>+</sup> and CD123<sup>-</sup>CD56<sup>-</sup> DCs with other immune cell lineages isolated from human peripheral blood based on their gene expression profiles. (D) The principal component analysis (PCA) results. Mono, monocytes; Neu, neutrophils; NK, natural killer cells.

lysosomal thiolreductase (GILT) is an essential enzyme for antigen processing, (Singh and Cresswell 2010; Maric et al., 2001) and we found that GILT and cathepsins were expressed at much higher levels in CD56<sup>+</sup> DCs than pDCs (Table S3). We next examined the antigen presentation by

CD56<sup>+</sup> DCs, pDCs and mDCs. Allogeneic naïve T cells were co-cultured with purified DCs and analyzed by tritium incorporation. The CD56<sup>+</sup> DCs stimulated comparable T-cell proliferation to mDCs, while pDCs did not induce significant T-cell expansion (Fig. 4G).



**Figure 4. CD56<sup>+</sup> DCs functionally resemble mDCs.** (A) The expression of TLR4 was quantified by RT-PCR with purified DCs. Error bars represent standard derivation from duplicated PCR samples of the same donor. Data shown are from one representative of 3 independent donors. (B) Lineage depleted PBMC were stimulated with LPS for 6 h, then the stimulated cells were collected and stained with surface markers followed by intracellular staining of TNF $\alpha$ . CD123<sup>+</sup>CD56<sup>-</sup> (pDC) CD123<sup>+</sup>CD56<sup>+</sup> (CD56<sup>+</sup>) and CD123<sup>-</sup>CD11C<sup>+</sup> (mDC) in the Lin<sup>-</sup> HLA-DR<sup>+</sup> gate were analyzed for TNF $\alpha$  expression. (C) Summarized data of (B) from 5 independent donors. (D) Purified DCs were stimulated with mixture of LPS, CpG and IFN $\gamma$  for 6 h, the expression of IL-12 p35 and p40 were analyzed by RT-PCR. Data shown are representative of 3 independent experiments. (E) Purified DCs were stimulated mixture of LPS, CpG and IFN $\gamma$  for 24 h, and the expression of IL-12 p70 were analyzed by ELISA. Data shown are representative of 2 independent experiments. (F) Expression of HLA-DR and CD86 on different blood DC subsets were analyzed by FACS. (G) Purified allogenic naive T cells were cocultured with different numbers of CD123<sup>+</sup>CD56<sup>-</sup> (pDC, circle) CD123<sup>+</sup>CD56<sup>+</sup> (CD56<sup>+</sup>, square) and CD123<sup>-</sup>CD11C<sup>+</sup> (mDC, triangle) DCs. After 5 days, the cocultured cells were pulsed with 1 mCi [<sup>3</sup>H] thymidine for 18 h before harvest. Data shown are one representative of 4 experiments.

#### CD56<sup>+</sup> DCs are unique mDCs mixed with some pDC features

CD56<sup>+</sup> DCs expressed BDCA2 and CD123, which were considered as hallmarks of pDCs (Fig. 1B). In order to further characterize the relationship between CD56<sup>+</sup> DCs and pDCs, we examined more pDC-specific genes at both RNA and protein levels in other DC subsets. And we found that BDCA4 and ILT7, two additional pDC specific surface markers, were expressed on CD56<sup>+</sup> DCs but not mDCs (Fig. 5A). Both E2-2 and SpiB, the two important transcription factors for pDC lineage development, were expressed in CD56<sup>+</sup> DCs at slightly lower levels than pDCs in the RNA-seq data (Table S4) and confirmed by RT-PCR (Fig. 5B, left two panels). It is worth to pointing out that the expression levels of E2-2 and SpiB in CD56<sup>+</sup> DCs were much higher than in mDCs (Fig. 5B, left two panels). In addition, pDC highly expressed genes IRF7, BCL11A and CD2AP

(Marafioti et al., 2008) were also expressed in CD56<sup>+</sup> DCs at a slightly lower level compared to pDCs (Table S4). However, other pDC specific genes, such as Granzyme B, TCL1A (Herling et al., 2003), PACSIN1 (Esashi et al., 2012) and BAD-LAMP (Defays et al., 2011), were expressed at least 10 times higher in pDCs than in CD56<sup>+</sup> DCs in RNA-seq data (Table S4).


We have already shown that CD56<sup>+</sup> DCs produced very low level IFN $\gamma$  upon CpG stimulation. And this is correlated with the lower expression level of TLR9 in CD56<sup>+</sup> DCs than pDCs. However, the expression of TLR9 in CD56<sup>+</sup> DCs is clearly higher than in mDCs (Fig. 5B, far right panel). Interestingly, CD56<sup>+</sup> DCs produced comparable levels of TNF $\alpha$  to those of pDCs upon CpG B stimulation (Fig. 5C-E). These results argue that CD56<sup>+</sup> DCs are unique comparing other mDCs by maintaining certain pDC characteristic features.

### BPDCN is closely related to CD56<sup>+</sup> DCs, but not pDCs by global gene expression profiling


In a previous report, we have found that BPDCN shows both myeloid and pDC characteristics (Cerboni et al., 2013). In order to clarify the relationship among BPDCN, pDC and CD56<sup>+</sup> DCs, we analyzed the differentially expressed genes between BPDCN and pDCs. We identified 127 genes express at higher levels in BPDCN than in pDC in cDNA array data (Fig. 6A, left panel; Table S7), but 93 (73%) of them are highly expressed in CD56<sup>+</sup> DCs compared to pDCs in our RNA-seq data (Fig. 6A, right panel). Similarly, there are 1143 genes expressed at lower levels in BPDCN cells than in pDCs (Fig. 6B, left panel; Table S8), and 778 (68%) of them are highly expressed in the CD56<sup>+</sup> DCs than pDCs (Fig. 6B, right panel). The global gene expression profiling data suggests that BPDCN is more closely related to the CD56<sup>+</sup> DCs than pDCs.

### DISCUSSION

CD4<sup>+</sup>CD56<sup>+</sup> hematologic malignancy with primary cutaneous presentation has been well documented and is proposed as the malignant counterpart of pDC precursors (Chaperot et al., 2001; Adachi et al., 1994; Brody 1995; Uchiyama 1998; Petrella et al., 1999) and was named as blastic plasmacytoid dendritic cell neoplasm (BPDCN) (Facchetti et al., 2008). Here in this report, we characterized a BDCA2<sup>+</sup>CD123<sup>+</sup>CD56<sup>+</sup> blood DC subset, which has been considered as a subpopulation of pDCs (Petrella et al., 2002). We demonstrated that the CD56<sup>+</sup> DCs clustered with mDCs by transcriptional profiling at whole genome level. Accordingly, CD56<sup>+</sup> DCs responded to TLR4 stimulation and prime naïve T cells without prior stimulation. And this agrees with our previous finding that BPDCN are characterized by their mixed pDC and myeloid signature (Sapienza et al., 2014). However, CD56<sup>+</sup> DCs are distinguished from other



**Figure 5. CD56<sup>+</sup> DCs adopt certain characteristics attributed to pDCs.** (A) The expression of BDCA4 and ILT7 in different DC subpopulations from PBMC were analyzed by FACS. Data shown are one representative of 3 donors. (B) CD123<sup>+</sup>CD56<sup>-</sup> (pDC), CD123<sup>+</sup>CD56<sup>+</sup> (CD56<sup>+</sup>) and CD123<sup>-</sup>CD11C<sup>+</sup> (mDC) were purified from PBMC, E2-2, Spi-B and TLR9 expression in those three DC populations were analyzed by RT-PCR. Error bars represent standard derivation from duplicated PCR samples of same donor. Data shown are one representative of 3 donors. (C) Purified DCs were stimulated with CpG B for 24 h, and the expression of TNF $\alpha$  were analyzed by ELISA. Data shown are summarized from 3 independent experiments. (D) Lineage depleted PBMCs were stimulated with CpG B for 6 h, then stimulated cells were collected and stained with Lin, HLA-DR, CD123, CD11C and CD56 followed by intracellular staining of TNF $\alpha$ . The Lin<sup>-</sup> HLA-DR<sup>+</sup> cells were divided into CD123<sup>+</sup>CD56<sup>-</sup> (pDC), CD123<sup>+</sup>CD56<sup>+</sup> (CD56<sup>+</sup>) and CD123<sup>-</sup>CD11C<sup>+</sup> (mDC) subsets, TNF $\alpha$  expression in each DC subset were analyzed. (E) Summarized data of (D) from 5 independent donors.



**Figure 6. Global gene expression of BPDCN, pDCs and CD56<sup>+</sup> DCs.** (A) Heat map of 127 genes highly expressed in BPDCN comparing with pDCs by cDNA array (left panel) and their expressions in CD56<sup>+</sup> DCs relative to CD56<sup>-</sup> pDCs by RNA-Seq (right panel). (B) Heat map of 1143 genes highly expressed in pDCs comparing with BPDCN by cDNA array (left panel) and their expressions in CD56<sup>+</sup> DCs relative to CD56<sup>-</sup> pDCs by RNA-Seq (right panel).

mDCs by expressing pDC specific molecules. Thus, we propose that CD56<sup>+</sup> DCs represent a unique mDC subset and their function in immune response warrant further characterization.

Besides BPDCN, another pDC related tumoral condition, pDC proliferations in patients with myeloid disorders (PPMD), has also been reported (Petrella and Facchetti 2010). The tumor cells of BPDCN and PPMD share the common characteristic phenotype of pDCs: lin<sup>-</sup>, CD4<sup>+</sup>, CD68<sup>+</sup>, CLA<sup>+</sup>, CD123<sup>+</sup>, BDCA2<sup>+</sup>, Bcl11A<sup>+</sup> and CD2AP<sup>+</sup>. However, CD56 expression, which is the hallmark of BPDCN, is not detected in PPMD (Petrella and Facchetti 2010; Vermi et al., 2004). Granzyme B (GrB) expresses at high level in pDCs (Rissoan et al., 2002) and is also positive in PPMD (Vermi et al., 2004). However, most reported BPDCN cases are GrB negative (Chaperot et al., 2001; Petrella et al., 2002; Pilichowska et al., 2007; An et al., 2013). Here in this study, we show CD56<sup>+</sup> DCs express much lower level of GrB compared to pDC (Table S4). We speculate that PPMD may be the tumor counterpart of pDC, while BPDCN may represent the counterpart of CD123<sup>+</sup>CD56<sup>+</sup> DCs. This hypothesis needs to be further investigated in the future by transcription profiling at whole genome level for both DC subsets and their tumor counterparts.

It is worth pointing out that the human CD123<sup>+</sup>CD56<sup>+</sup> DCs are similar to a CX<sub>3</sub>CR1<sup>+</sup>CD8<sup>+</sup> mouse DC subset, which also exhibits mixed characteristics of pDC and mDC (Ghosh et al., 2010). The CX<sub>3</sub>CR1<sup>+</sup>CD8<sup>+</sup> mouse DCs are

developmentally dependent on E2-2 and express pDC specific genes (Spi-B, Siglec H, Bst2). However, CX<sub>3</sub>CR1<sup>+</sup>CD8<sup>+</sup> DCs do not produce IFN $\alpha$  upon TLR7 and TLR9 stimulation (Ghosh et al., 2010). The CX<sub>3</sub>CR1<sup>+</sup>CD8<sup>+</sup> DC is transcriptionally similar to mouse CD8<sup>+</sup> mDCs, but not to CD8<sup>+</sup> mDCs (Ghosh et al., 2010). The developmental relationship between human CD56<sup>+</sup> DCs and mouse CX<sub>3</sub>CR1<sup>+</sup>CD8<sup>+</sup> DCs needs further investigation.

Taken together, we have demonstrated that human CD56<sup>+</sup> DCs were very close to mDC by both transcriptomic analysis and functional characterization. Thus, we propose that CD56<sup>+</sup> DC should be classified as mDC, but not pDCs. And we propose that BPDCN should be classified as mDC but not pDC related leukemia.

## MATERIALS AND METHODS

### FACS analysis of DC subsets in human blood

For analysis of DC subsets in human peripheral blood, single cells were first gated by light scatters and dead cells were excluded by yellow fluorescent reactive live/dead cell dye staining (Life Technologies, Carlsbad, USA), then the lineage positive cells were gated out by specific markers (CD3, CD14, CD16, CD19). HLA-DR<sup>+</sup>CD123<sup>+</sup>BDCA2<sup>+</sup> cells were further divided by their CD2 and CD56 expression. Antibody stained peripheral blood mononuclear cells (PBMC) were analyzed with LSRfortessa (BD Biosciences, Franklin Lakes, NJ, USA) and data were analyzed with Summit 4.3

(DAKO, Denmark). Detailed information of antibodies used for flow cytometry analysis was shown in Table S5.

#### DC enrichment and *in vitro* stimulation

DCs were enriched by lineage (CD3, CD14, CD16, CD19) depletion, then lineage negative cells ( $2 \times 10^5$  in 200  $\mu\text{L}$  culture medium) were stimulated with TLR ligands or viruses for 4 h followed by another 2 h in the presence of Golgi Blocker (BD Biosciences, Franklin Lakes, NJ, USA). Cells were stained with surface markers and permeabilized and stained with antibodies against various cytokines. TLR ligands were purchased from Invivogen (San Diego, CA, USA) and used at following concentrations: LPS (1  $\mu\text{g/mL}$ ), CpG 2216 (2  $\mu\text{g/mL}$ ), R848 (2  $\mu\text{g/mL}$ ). Heat inactivated influenza virus A/PR8/34 was used at 10 MOI for stimulation.

#### DC purification and stimulation

The lineage (CD3, CD14, CD16, CD19, CD20) depleted PBMC were stained with HLA-DR (APC-Cy7), CD2 (PE-Cy7), CD11c (APC), CD56 (PerCP-cy5.5) and CD123 (BV421). Lin<sup>-</sup>HLA-DR<sup>+</sup>CD123<sup>+</sup>CD11c<sup>-</sup>CD2<sup>+</sup>CD56<sup>+</sup> and Lin<sup>-</sup>HLA-DR<sup>+</sup>CD123<sup>+</sup>CD11c<sup>-</sup>CD2<sup>-</sup>CD56<sup>-</sup> DCs were sorted with BD FACS Aria III (BD Biosciences, Franklin Lakes, NJ, USA). In some experiments, Lin<sup>-</sup>HLA-DR<sup>+</sup>CD123<sup>-</sup>CD11c<sup>+</sup> mDC were sorted as control. Purified DCs ( $1 \times 10^4$  in 200  $\mu\text{L}$  culture medium) were stimulated with different TLR ligands at the concentration mentioned above. For IL-12 production, purified DCs were stimulated with LPS, CpG 2006 (1  $\mu\text{mol/L}$ ) and IFNy (50 ng/mL). IFN $\alpha$ , IL-12 and TNF $\alpha$  levels in the supernatant were quantified by ELISA.

#### RNA-seq and data analysis

RNA extraction and sequencing were done by BGI Tech (Shenzhen, Guangdong, China). The gene expression level was measured by the number of uniquely mapped reads per kilobase of exon region per million mappable reads (RPKM). The RNA-seq raw data was aligned to the reference genome (hg19) (Trapnell et al., 2009). The gene expressions of other cell types used in our study were obtained from cDNA array data by Scott H Robbins (Robbins et al., 2008). The target gene regions of microarray probes were retrieved from the annotation file for human U133 Plus 2.0 (<http://www.affymetrix.com>). To compare gene expressions from both RNA-seq and cDNA array experiments, we only considered the reads that have at least one nucleotide overlap with the gene regions targeted by microarray probes. Heat maps were generated with differentially expressed genes between CD2<sup>+</sup>CD56<sup>+</sup> and CD2<sup>-</sup>CD56<sup>-</sup> DCs (larger than 2 times difference). Transcriptome comparison of CD2<sup>+</sup>CD56<sup>+</sup> DCs and other blood cells lineages were carried out with two different mathematical methods, hierarchical clustering with complete linkage (Eisen et al., 1998) and principal component analysis (PCA) (Alter et al., 2000). Detailed methods of RNA-seq and data analysis were provided in the supplemental file.

BPDCN microarray data of 6 cryopreserved tissue samples (Sapienza et al., 2014) by Affymetrix microarray platform were normalized with the rank invariant method using Lumi (Bioconductor) (Du et al., 2008). Statistics for differential expression were applied by

Limma (Bioconductor), (Smyth 2004) and we defined BPDCN significant differential expressed genes on normalized data as adjusted *P*-value less than 0.05. One hundred and twenty seven BPDCN highly expressed genes and 1143 BPDCN lowly expressed genes were matched to our RNA-seq datasets of pDC and CD56<sup>+</sup> DCs (genes with RPKM less than 10 were deleted). Heat maps were displayed using the R software.

#### RT-PCR

RNA was extracted from purified DCs and reverse transcribed with Oligo dT primers. Quantitative real time PCR (RT-PCR) was performed using cDNA with EF1 $\alpha$  gene as internal control. Primers for RT-PCR are listed in Table S6.

#### T-cell proliferation assay

Human CD4<sup>+</sup>CD45RA<sup>+</sup> naïve T cells were purified from PBMC by negative selection with magnetic beads (Miltenyi Biotech, Germany). Different numbers of FACS purified DCs were cultured with  $5 \times 10^4$  allogeneic naïve T cells in 96-well round-bottomed plates in 200  $\mu\text{L}$  culture medium. After 5 days of DC and T cell co-culture, cells were pulsed with 1 mCi [<sup>3</sup>H]-thymidine for 18 h before harvest. Radioactive uptake was measured with a TopCount NXT micro-plate scintillation and luminescence counter (PerkinElmer).

#### ACKNOWLEDGMENTS

This work was supported by grants from Beijing Municipal Science & Technology Commission (SCW 2014-09), Chinese Academy of Science (KJZD-EW-L10-02) and Ministry of Health (2013ZX10001002) to L.Z. The authors thank Dr. Lishan Su for critical reading this manuscript and Mr. Anthony Curtis for English editing. H.Y. and L.Z. designed the project, analyzed data and wrote the paper; P.Z., Y.C. and T.J. analyzed and interpreted the RNA-seq data and wrote the paper; P. P. participated in the analysis of BPDCN data; X.Y., Z.Y., Q.S., S.W. and G.L. performed experiments and analyzed data. The authors declare no financial conflict of interest in relation to this work.

#### ABBREVIATIONS

BPDCN, blastic plasmacytoid dendritic cell neoplasm; DCs, dendritic cells; IFN-I, type I interferon; IRF7, interferon regulatory factor 7; mDC, myeloid DC; PBMC, peripheral blood mononuclear cell; PCA, principal component analysis; pDC, plasmacytoid DC; TLR, toll like receptor.

#### COMPLIANCE WITH ETHICS GUIDELINES

Haisheng Yu, Peng Zhang, Xiangyun Yin, Zhao Yin, Quanxing Shi, Ya Cui, Guanyuan Liu, Shouli Wang, Pier Paolo Piccaluga, Taijiao Jiang and Liguo Zhang declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

## OPEN ACCESS

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

## REFERENCES

Adachi M, Maeda K, Takekawa M et al (1994) High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. *Am J Hematol* 47(4):278–282

Alter O, Brown PO, Botstein D (2000) Singular value decomposition for genome-wide expression data processing and modeling. *Proc Natl Acad Sci USA* 97(18):10101–10106

An HJ, Yoon DH, Kim S et al (2013) Blastic plasmacytoid dendritic cell neoplasm: a single-center experience. *Ann Hematol* 92(3):351–356

Brody JP, Allen S, Schulman P et al (1995) Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. *Cancer* 75(10):2474–2483

Cao W, Rosen DB, Ito T et al (2006) Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. *J Exp Med* 203(6):1399–1405

Cella M, Jarrossay D, Facchetti F et al (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. *Nat Med* 5(8):919–923

Cerboni S, Gentili M, Manel N (2013) Diversity of pathogen sensors in dendritic cells. *Adv Immunol* 120:211–237

Chaperot L, Bendriss N, Manches O et al (2001) Identification of a leukemic counterpart of the plasmacytoid dendritic cells. *Blood* 97(10):3210–3217

Cisse B, Caton ML, Lehner M et al (2008) Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. *Cell* 135(1):37–48

Comeau MR (2002) Van der Vuurst de Vries AR, Maliszewski CR, Galibert L. CD123bright plasmacytoid predendritic cells: progenitors undergoing cell fate conversion? *J Immunol* 169(1):75–83

Defays A, David A, de Gassart A et al (2011) BAD-LAMP is a novel biomarker of nonactivated human plasmacytoid dendritic cells. *Blood* 118(3):609–617

Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 24(13):1547–1548

Dzionek A, Fuchs A, Schmidt P et al (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. *J Immunol* 165(11):6037–6046

Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. *Proc Natl Acad Sci USA* 95(25):14863–14868

Esashi E, Bao M, Wang YH, Cao W, Liu YJ (2012) PACSIN1 regulates the TLR7/9-mediated type I interferon response in plasmacytoid dendritic cells. *Eur J Immunol* 42(3):573–579

Facchetti F, Jones D, Petrella T (2008) Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow S, Campo E, Harris N et al (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer (IARC), Lyon, pp 145–147

Ghosh HS, Cisse B, Bunin A, Lewis KL, Reizis B (2010) Continuous expression of the transcription factor e2-2 maintains the cell fate of mature plasmacytoid dendritic cells. *Immunity* 33(6):905–916

Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ (1997) The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. *J Exp Med* 185(6):1101–1111

Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4<sup>+</sup> CD56<sup>+</sup> blastic tumors of skin. *Blood* 101(12):5007–5009

Kadowaki N, Ho S, Antonenko S et al (2001) Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. *J Exp Med* 194(6):863–869

Liu YJ (2005) IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu Rev Immunol* 23:275–306

Marafioti T, Paterson JC, Ballabio E et al (2008) Novel markers of normal and neoplastic human plasmacytoid dendritic cells. *Blood* 111(7):3778–3792

Maric M, Arunachalam B, Phan UT et al (2001) Defective antigen processing in GLT-free mice. *Science* 294(5545):1361–1365

Matsui T, Connolly JE, Michnevitz M et al (2009) CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. *J Immunol* 182(11):6815–6823

Petrella T, Facchetti F (2010) Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009? *Autoimmunity* 43(3):210–214

Petrella T, Dalac S, Maynadie M et al (1999) CD4<sup>+</sup> CD56<sup>+</sup> cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutane (GFELC). *Am J Surg Pathol* 23(2):137–146

Petrella T, Comeau MR, Maynadie M et al (2002) 'Agranular CD4<sup>+</sup> CD56<sup>+</sup> hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56<sup>+</sup> precursor cells related to plasmacytoid monocytes. *Am J Surg Pathol* 26(7):852–862

Pilichowska ME, Fleming MD, Pinkus JL, Pinkus GS (2007) CD4<sup>+</sup> CD56<sup>+</sup> hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. *Am J Clin Pathol* 128(3):445–453

Rissoan MC, Duhen T, Bridon JM et al (2002) Subtractive hybridization reveals the expression of immunoglobulin-like transcript 7, Eph-B1, granzyme B, and 3 novel transcripts in human plasmacytoid dendritic cells. *Blood* 100(9):3295–3303

Robbins SH, Walzer T, Dembele D et al (2008) Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. *Genome Biol* 9(1):R17

Sapienza MR, Fuligni F, Agostinelli C et al (2014) Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique

pattern and suggests selective sensitivity to NF- $\kappa$ B pathway inhibition. *Leukemia* 28:1606–1616

Schotte R, Nagasawa M, Weijer K, Spits H, Blom B (2004) The ETS transcription factor Spi-B is required for human plasmacytoid dendritic cell development. *J Exp Med* 200(11):1503–1509

Siegal FP, Kadewaki N, Shodell M et al (1999) The nature of the principal type 1 interferon-producing cells in human blood. *Science* 284(5421):1835–1837

Singh R, Cresswell P (2010) Defective cross-presentation of viral antigens in GILT-free mice. *Science* 328(5984):1394–1398

Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. *Stat Appl Genet Mol Biol* 3:1–25

Steinman RM (2007) Lasker Basic Medical Research Award. Dendritic cells: versatile controllers of the immune system. *Nat Med* 13(10):1155–1159

Trapnell C, Pachter L, Salzberg SL (2009) TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* 25(9):1105–1111

Uchiyama N, Ito K, Kawai K, Sakamoto F, Takaki M, Ito M (1998) CD2<sup>−</sup>, CD4<sup>+</sup>, CD56<sup>+</sup> agranular natural killer cell lymphoma of the skin. *Am J Dermatopathol* 20(5):513–517

Vermi W, Facchetti F, Rosati S et al (2004) Nodal and extranodal tumor-forming accumulation of plasmacytoid monocytes/interferon-producing cells associated with myeloid disorders. *Am J Surg Pathol* 28(5):585–595

Ziegler-Heitbrock L, Ancuta P, Crowe S et al (2010) Nomenclature of monocytes and dendritic cells in blood. *Blood* 116(16):e74–e80